Marksans Pharma · NSE: MARKSANS · BSE: 524404
Q4 FY20 results · Jan–Mar 2020
Marksans Pharma reported revenue from operations of ₹335.35 crore (up 35.5% from Q4 FY19) and net profit of ₹42.74 crore (up 333.8% from Q4 FY19) for Q4 FY20 (Jan–Mar 2020), on a consolidated basis.
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 335.35 | 247.41 | +35.5% | 287.65 | +16.6% |
| Other income | 0.03 | 9.73 | −99.7% | 0.03 | +0.0% |
| Total income | 335.38 | 257.14 | +30.4% | 287.68 | +16.6% |
| Profit before tax | 57.56 | 16.68 | +245.2% | 38.34 | +50.2% |
| Net profit for the period | 42.74 | 9.85 | +333.8% | 29.56 | +44.6% |
| EPS, basic (₹) | 1.00 | 0.21 | +376.2% | 0.71 | +40.8% |
| Net margin (%) | 12.7 | 4.0 | 10.3 |
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 113.64 | 91.18 | +24.6% | 116.88 | −2.8% |
| Other income | (0.08) | 9.50 | Turned loss | 0.01 | Turned loss |
| Total income | 113.55 | 100.69 | +12.8% | 116.89 | −2.8% |
| Profit before tax | 13.17 | 8.82 | +49.4% | 16.12 | −18.3% |
| Net profit for the period | 7.41 | 5.62 | +31.8% | 12.97 | −42.9% |
| EPS, basic (₹) | 0.18 | 0.14 | +28.6% | 0.32 | −43.8% |
| Net margin (%) | 6.5 | 6.2 | 11.1 |
Consolidated
- Filed with BSE
- 02 Jun 2020, 17:06 IST
- Board meeting
- 02 Jun 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 02 Jun 2020, 17:06 IST
- Board meeting
- 02 Jun 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE